CR11864A - Preparación de formas farmacéuticas relajantes de músculos esqueléticos de liberación controlada - Google Patents

Preparación de formas farmacéuticas relajantes de músculos esqueléticos de liberación controlada

Info

Publication number
CR11864A
CR11864A CR11864A CR11864A CR11864A CR 11864 A CR11864 A CR 11864A CR 11864 A CR11864 A CR 11864A CR 11864 A CR11864 A CR 11864A CR 11864 A CR11864 A CR 11864A
Authority
CR
Costa Rica
Prior art keywords
skelettic
relaxing
muscles
preparation
controlled release
Prior art date
Application number
CR11864A
Other languages
English (en)
Inventor
Gopi Venkatesh
Timothy Grinstead
James Clvenger
Original Assignee
Saunders Robert Mitchel
Spin Free Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41434443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11864(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Saunders Robert Mitchel, Spin Free Llc filed Critical Saunders Robert Mitchel
Publication of CR11864A publication Critical patent/CR11864A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método para preparar una composición farmacéutica de liberación prolongada que comprende ciclobenzaprina, que comprende recubrir partículas inertes con una composición estratificante de fármaco que contiene ciclobenzaprina para formar microesferas LI.
CR11864A 2008-06-20 2010-12-21 Preparación de formas farmacéuticas relajantes de músculos esqueléticos de liberación controlada CR11864A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7446408P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
CR11864A true CR11864A (es) 2011-05-16

Family

ID=41434443

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11864A CR11864A (es) 2008-06-20 2010-12-21 Preparación de formas farmacéuticas relajantes de músculos esqueléticos de liberación controlada

Country Status (28)

Country Link
US (3) US20090148532A1 (es)
EP (1) EP2303020B1 (es)
JP (1) JP5636364B2 (es)
KR (1) KR101451823B1 (es)
CN (2) CN106860430A (es)
AR (2) AR072267A1 (es)
AU (1) AU2009259993B2 (es)
BR (1) BRPI0914225B1 (es)
CA (1) CA2727935C (es)
CL (1) CL2009001447A1 (es)
CO (1) CO6300903A2 (es)
CR (1) CR11864A (es)
CY (1) CY1118878T1 (es)
DK (1) DK2303020T3 (es)
ES (1) ES2625485T3 (es)
HU (1) HUE032182T2 (es)
IL (1) IL209997A0 (es)
MX (1) MX2010013760A (es)
MY (2) MY173408A (es)
NZ (1) NZ589856A (es)
PL (1) PL2303020T3 (es)
PT (1) PT2303020T (es)
RU (1) RU2540494C2 (es)
SG (1) SG193816A1 (es)
TW (2) TWI458480B (es)
UY (1) UY31928A (es)
WO (1) WO2009155426A1 (es)
ZA (2) ZA201009083B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
RS56634B1 (sr) * 2009-11-20 2018-03-30 Tonix Pharma Holdings Ltd Postupci i kompozicije za lečenje simptoma povezanih sa posttraumatskim stresnim poremećajem korišćenjem ciklobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
US20150086626A1 (en) * 2012-04-17 2015-03-26 Mylan, Inc Stable dosage forms of skeletal muscle relaxants with extended release coating
LT2861223T (lt) * 2012-06-15 2022-12-12 Tonix Pharma Holdings Limited Kompozicijos ir būdai, skirti absorbavimui per gleivinę
ES2769879T3 (es) 2013-03-15 2020-06-29 Tonix Pharma Holdings Ltd Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol
CA2961822A1 (en) 2014-09-18 2016-03-24 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
EA201992116A1 (ru) * 2017-03-08 2020-01-29 СИНРКС ФАРМА, ЭлЭлСи Фармацевтические составы флороглюцинола и триметилфлороглюцинола
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
CN109381446A (zh) * 2018-11-26 2019-02-26 正大制药（青岛）有限公司 一种盐酸环苯扎林缓释胶囊
CN111374942B (zh) * 2018-12-30 2022-09-13 鲁南制药集团股份有限公司 一种甾体类肌松药注射液及其制备方法
CN114432266B (zh) * 2021-12-23 2023-03-10 南通联亚药业股份有限公司 一种稳定的盐酸环苯扎林缓释胶囊

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882246A (en) * 1971-05-21 1975-05-06 Merck & Co Inc Treatment of skeletal muscle disorders with cyclobenzaprine
US4337582A (en) * 1980-09-30 1982-07-06 Airco, Inc. Methods for controlling vapor concentrations in an atmosphere
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US5047258A (en) * 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
WO2001019901A2 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
US6576702B2 (en) 2000-07-20 2003-06-10 Noveon Ip Holdings Corp. Plasticized waterborne polyurethane dispersions and manufacturing process
WO2003082207A2 (en) * 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
EP1689367A1 (en) * 2003-10-21 2006-08-16 Actavis Group HF Pharmaceutical formulations containing quetiapine
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
EP1791531A1 (en) * 2004-08-20 2007-06-06 Alpharma, Inc. Paroxetine formulations
US20060263429A1 (en) * 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
ZA200807943B (en) * 2006-03-24 2009-11-25 Panacea Biotec Ltd Antibiotic compositions of modified release and process of production thereof
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms

Also Published As

Publication number Publication date
HUE032182T2 (en) 2017-09-28
BRPI0914225A8 (pt) 2018-02-06
AR072267A1 (es) 2010-08-18
EP2303020B1 (en) 2017-02-22
CY1118878T1 (el) 2018-01-10
US20100098832A1 (en) 2010-04-22
AU2009259993A1 (en) 2009-12-23
IL209997A0 (en) 2011-02-28
BRPI0914225A2 (pt) 2017-11-07
RU2011101918A (ru) 2012-07-27
ZA201009083B (en) 2012-03-28
JP2011525188A (ja) 2011-09-15
NZ589856A (en) 2012-06-29
US20090148532A1 (en) 2009-06-11
KR20110025654A (ko) 2011-03-10
CA2727935A1 (en) 2009-12-23
CN106860430A (zh) 2017-06-20
JP5636364B2 (ja) 2014-12-03
CO6300903A2 (es) 2011-07-21
BRPI0914225B1 (pt) 2021-08-31
MY153712A (en) 2015-03-13
RU2540494C2 (ru) 2015-02-10
MX2010013760A (es) 2011-03-29
PL2303020T3 (pl) 2017-08-31
ZA201109534B (en) 2013-10-30
ES2625485T3 (es) 2017-07-19
CA2727935C (en) 2017-05-30
TW201503915A (zh) 2015-02-01
US20120196028A1 (en) 2012-08-02
PT2303020T (pt) 2017-06-02
SG193816A1 (en) 2013-10-30
AR113877A2 (es) 2020-06-24
AU2009259993B2 (en) 2013-10-31
EP2303020A1 (en) 2011-04-06
EP2303020A4 (en) 2013-12-04
CL2009001447A1 (es) 2009-08-21
TWI458480B (zh) 2014-11-01
WO2009155426A1 (en) 2009-12-23
DK2303020T3 (en) 2017-05-01
US8137734B2 (en) 2012-03-20
TW201004615A (en) 2010-02-01
UY31928A (es) 2010-01-29
MY173408A (en) 2020-01-22
KR101451823B1 (ko) 2014-10-16
CN102065691A (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
CR11864A (es) Preparación de formas farmacéuticas relajantes de músculos esqueléticos de liberación controlada
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
BR112014001279A2 (pt) composto, uso do composto, composição farmacêutica, e, método para tratar um indivíduo que sofre com um distùrbio mediado pela tirosina cinase de bruton (btk)
ECSP10010295A (es) Formulacion de anticuerpo
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
BR112012032816A2 (pt) composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE
BRPI0906475A2 (pt) Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
BR112012024432A2 (pt) composição farmacêutica de dissolução rápida
NI201100016A (es) Formulaciones farmacéuticas que contienen ligandos de receptores de dopamina.
CL2013000200A1 (es) Una composicion de combinacion farmaceutica que comprende una forma activa potenciada de un anticuerpo al receptor de la insulina humana y una forma activa potenciada de un anticuerpo de la sintasa de no endotelial; metodo para tratar la diabetes y los trastornos metabolicos.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
BR112014002557A2 (pt) uso de uma composição curável, composição curável, processo para o encapsulamento de um transformador de medida e, tranformador de medida
TN2009000510A1 (en) Extended release formulation of nevirapine
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
BR112014009500A2 (pt) método in vitro para a liberação de um composto de vitamina d, método in vitro para medição de um composto de vitamina d e uso de uma composição reagente
BRPI0922714A2 (pt) composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos
BRPI0923003A2 (pt) composição de liberação controlada para produção de uma preparação de liberação prolongada contendo udenafil